Abstract
Background & aims
Long-term outcomes of patients with branch-duct intraductal papillary mucinous neoplasms (IPMNs), particularly those after 5 years of surveillance, have not been fully evaluated in large studies. We analyzed incidences of IPMN-derived carcinoma and concomitant ductal adenocarcinoma (pancreatic ductal adenocarcinoma [PDAC]) over 20 years in a large population of patients.Methods
We identified 1404 consecutive patients (52% women; mean age, 67.5 years) with a diagnosis of branch-duct IPMN, from 1994 through 2017, at the University of Tokyo in Japan. Using a competing risk analysis, we estimated cumulative incidence of pancreatic carcinoma, overall and by carcinoma type. We used competing risks proportional hazards models to estimate subdistribution hazard ratios (SHRs) for incidences of carcinomas. To differentiate IPMN-derived and concomitant carcinomas, we collected genomic DNA from available paired samples of IPMNs and carcinomas and detected mutations in GNAS and KRAS by polymerase chain reaction and pyrosequencing.Results
During 9231 person-years of follow-up, we identified 68 patients with pancreatic carcinomas (38 patients with IPMN-derived carcinomas and 30 patients with concomitant PDACs); the overall incidence rates were 3.3%, 6.6%, and 15.0% at 5, 10, and 15 years, respectively. Among 804 patients followed more than 5 years, overall cumulative incidence rates of pancreatic carcinoma were 3.5% at 10 years and 12.0% at 15 years from the initial diagnosis. The size of the IPMN and the diameter of the main pancreatic duct associated with incidence of IPMN-derived carcinoma (SHR 1.85; 95% confidence interval 1.38-2.48 for a 10-mm increase in the IPMN size and SHR 1.56; 95% confidence interval 1.33-1.83 for a 1-mm increase in the main pancreatic duct diameter) but not with incidence of concomitant PDAC.Conclusions
In a large long-term study of patients with branch-duct IPMNs, we found the 5-year incidence rate of pancreatic malignancy to be 3.3%, reaching 15.0% at 15 years after IPMN diagnosis. We observed heterogeneous risk factor profiles between IPMN-derived and concomitant carcinomas.Full text links
Read article at publisher's site: https://doi.org/10.1053/j.gastro.2019.08.032
Read article for free, from open access legal sources, via Unpaywall: http://www.gastrojournal.org/article/S0016508519412572/pdf
Citations & impact
Impact metrics
Article citations
Development of an intraductal papillary mucinous neoplasm malignancy prediction scoring system.
PLoS One, 19(10):e0312234, 17 Oct 2024
Cited by: 0 articles | PMID: 39418295 | PMCID: PMC11486388
Early detection of concomitant pancreatic cancer during intraductal papillary mucinous neoplasms surveillance.
Gland Surg, 13(9):1659-1661, 12 Sep 2024
Cited by: 0 articles | PMID: 39421055 | PMCID: PMC11480875
Precision Targeting Strategies in Pancreatic Cancer: The Role of Tumor Microenvironment.
Cancers (Basel), 16(16):2876, 19 Aug 2024
Cited by: 0 articles | PMID: 39199647 | PMCID: PMC11352254
Review Free full text in Europe PMC
Comparison of intra- and inter-reader agreement of abbreviated versus comprehensive MRCP for pancreatic cyst surveillance.
Abdom Radiol (NY), 49(10):3517-3527, 18 Jun 2024
Cited by: 0 articles | PMID: 38888739
Pancreatic cancer risk in diabetic patients using the Japanese Regional Insurance Claims.
Sci Rep, 14(1):16958, 23 Jul 2024
Cited by: 0 articles | PMID: 39043788 | PMCID: PMC11266625
Go to all (79) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Assessment of clonality of multisegmental main duct intraductal papillary mucinous neoplasms of the pancreas based on GNAS mutation analysis.
Surgery, 157(2):277-284, 16 Dec 2014
Cited by: 11 articles | PMID: 25530484
Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
Ann Surg, 258(1):141-151, 01 Jul 2013
Cited by: 61 articles | PMID: 23532108
Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation.
PLoS One, 9(6):e98718, 04 Jun 2014
Cited by: 31 articles | PMID: 24897499 | PMCID: PMC4045804
Clinical assessment of the GNAS mutation status in patients with intraductal papillary mucinous neoplasm of the pancreas.
Surg Today, 49(11):887-893, 16 Mar 2019
Cited by: 10 articles | PMID: 30879148
Review
Funding
Funders who supported this work.